Celltrion gets green light to sell Truxima in AustraliaCelltrion said Friday it has won approval from an Australian regulator for the sale of its biosimilar drug Truxima.
The Therapeutic Goods Administration accepted Celltrion’s application to sell the biosimilar to Roche’s MabThera, the company said. The antibody biosimilar is used in the treatment of a number of diseases, including rheumatoid arthritis and non-Hodgkin’s lymphoma, a type of leukemia.
With the approval, Truxima would be Celltrion’s second drug, after Remsima, to hit the Australian market, company sources said.
More in Industry
Move over Federer
Hanjin KAL slams largest shareholder, accusing it of peddling lies
Tech firms brief president on state of AI research
Dongsuh recognizes female authors at Scent of Life Awards